UBS Group
CSTL icon

UBS Group’s Castle Biosciences CSTL Stock Holding History

UBS Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26,400
Closed -$704K – 10291
2024
Q4 		$704K Hold
26,400
– – ﹤0.01% 5605
2024
Q3 		$753K Buy
+26,400
New +$672K ﹤0.01% 4900
2021
Q1 		– Sell
-15,000
Closed -$1.01M – 9053
2020
Q4 		$1.01M Buy
+15,000
New +$813K ﹤0.01% 4019

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's CSTL Position: Q1 2026 in Review

UBS Group reduced its Castle Biosciences (CSTL) stake by 65% in Q1 2026, selling an estimated $3.04M and leaving 49,163 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #5403.

UBS Group first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $21.7M in Q4 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • UBS Group held 49,163 shares of Castle Biosciences worth $1.21M as of Q1 2026.
  • UBS Group sold 92,710 Castle Biosciences shares in Q1 2026, an estimated $3.04M.
  • Castle Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5403 holding.
  • UBS Group first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • UBS Group's Castle Biosciences position peaked at $21.7M in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.